OOIR: Observatory of International Research

Papers

(The H4-Index of Oncologist is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	166
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial	100
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	89
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	89
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	75
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	75
Calls to action on lung cancer management and research	69
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	59
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	57
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	57
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	56
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data	48
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	46
Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics	46
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results	41
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	41
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation	38
Evaluating the Effectiveness of Mobile Health in Breast Cancer Care: A Systematic Review	37
Prevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer	37
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer	37
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1	36
Exploring immune activation patterns in HER2-low and HER2-ultralow breast cancer subtypes	35
56 Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer	35
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events	33
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	33

Classification of NK-large granular lymphocytic leukemia by CD56 expression	32
Contextualizing results of randomized trials in smoldering myeloma	32
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	32
A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	32
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management	32
ALK-positive Adult Histiocytosis With a TFG-ALK Fusion Gene: A Case Report	31
Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma	31
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy	31